Search

Displaying results 2181 - 2190 of 9702 in total
  1. Drug

    Belatacept

    go.drugbank.com/drugs/DB06681
    ApprovedInvestigational

    Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. … The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. It is approved for the treatment of rheumatoid arthritis.

  2. Drug

    Oxymetazoline

    go.drugbank.com/drugs/DB00935
    ApprovedInvestigational

    Oxymetazoline is an imidazole derivative and a potent, direct-acting alpha (α)-adrenergic agonist with affinity to both α<sub>1</sub>- and α<sub>2</sub>-adrenoceptors. … [A215542] Oxymetazoline is available in various formulations with a wide variety of clinical implications. The topical formulation of the drug is used to treat persistent facial redness in adults.

  3. Drug

    Escitalopram

    go.drugbank.com/drugs/DB01175
    ApprovedInvestigational

    Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram].

    Categories: Monoamine Oxidase A SubstratesProducts: ESCITALOPRAM 1A 20MG/ML, ESCITALOPRAM AL 5MG FTA
  4. Drug

    Pentoxyverine

    go.drugbank.com/drugs/DB11186
    ApprovedWithdrawn

    Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant [A32717], and local anesthetic properties.

    Mixtures: Pancold AProducts: PENTOXYVERIN AL 19MG/ML, PENTOXYVERIN AL 1.35 MG/ML
  5. Drug

    Benmelstobart

    go.drugbank.com/drugs/DB17473
    Investigational

    APL 502 is a humanised immunoglobulin G1 (IgG1) monoclonal antibody targeting the programmed cell death-1 ligand-1 (PD-L1).

  6. Drug

    DTx-1252

    go.drugbank.com/drugs/DB18086
    Experimental

    DTx-1252 is a siRNA therapeutic under investigation for the treatment of Charcot-Marie-Tooth Disease type 1A (CMTD1A).[L48096]

  7. Drug

    CSIC002

    go.drugbank.com/drugs/DB18584
    Experimental

    CSIC002 is a small-molecule Sema-3A inhibitor. It is being investigated for the treatment of anterior ischemic optic neuropathy.

  8. Drug

    LY-2881835

    go.drugbank.com/drugs/DB15046
    Investigational

    LY-2881835 is under investigation in clinical trial NCT01358981 (A Study of LY2881835 in Healthy People and People With Diabetes).

  9. Drug

    AK106-001616

    go.drugbank.com/drugs/DB16058
    Investigational

    AK106-001616 is under investigation in clinical trial NCT01285752 (A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)).

  10. Drug

    LY-3200882

    go.drugbank.com/drugs/DB16064
    Investigational

    LY-3200882 is under investigation in clinical trial NCT04158700 (A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer).